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Peptide mimotopes of tumor antigen epitopes have been proposed as components of tumor vaccines. In this study,
we determined the immunogenicity of melcam mim1 and melcam mim2, peptide mimics of an epitope of the
melanoma cell-adhesion molecule (Mel-CAM). BALB/c mice were vaccinated either with mimotopes or mimotopes
coupled to tetanus toxoid (TT). The antibody responses of mice to melcam mim1, melcam mim2, and recombinant
Mel-CAM were analyzed by an ELISA and immunoblot analyses. TT-coupled mimotopes led to high titers of IgG
mainly of the IgG2a subclass to melcam mim1 and melcam mim2. Immunization with each of the mimotope for-
mulations induced antibodies that cross-reacted with recombinant Mel-CAM. Uncoupled mimotopes induced
lymphocyte proliferation and cytokine production in spleen cell cultures indicating that both peptide mimotopes
also contained T cell epitopes. TT-coupled mimotopes induced T helper (Th)1 (interleukin (IL)-2, interferon-c) and
Th2 (IL-4, IL-5) cytokines, whereas uncoupled mimotopes induced a Th1-biased T cell response. Our results sug-
gest that mimotopes potentially represent a novel vaccine approach to induce a tumor antigen-specific humoral
and cellular response.
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Melanoma cell-adhesion molecule (Mel-CAM) is an integral
membrane glycoprotein with a molecular mass of 113 kDa
and contains several protein kinase recognition motifs in
its cytoplasmic domain, suggesting an involvement in cell
signalling (Shih, 1999). Mel-CAM is strongly upregulated
in melanomas as compared with benign lesions and ex-
pressed by more than 80% of metastatic lesions (Kraus
et al, 1997). Recent data suggest that Mel-CAM is involved
in cell–cell adhesion (Satyamoorthy et al, 2001). The ex-
pression of Mel-CAM on melanoma cells correlates with an
invasive phenotype indicating its use as a cell surface
marker of metastasis formation and tumor progression (Xie
et al, 1997). Mel-CAM has been shown to be involved in
tumor–endothelial cell interaction that might be part of the
extravasation process of tumor cells (Johnson et al, 1997;
Shih et al, 1997). These findings have defined Mel-CAM as a
candidate for mediating tumor growth and metastases and
therefore blocking Mel-CAM might be a potential target for
immunotherapy directed against several Mel-CAM express-
ing tumors. Fully human antibodies to Mel-CAM inhibited
tumor growth and metastasis of human melanoma and
spontaneous pulmonary metastasis of osteosarcoma in
nude mice, indicating the usefulness of this protein for new
antibody-based immunotherapeutic approaches (Mills et al,
2002; McGary et al, 2003). The development of an epitope-
based synthetic peptide vaccine to induce antibodies
against Mel-CAM seems to be a valid new approach. This
requires the identification of B cell epitopes capable of in-
ducing immune responses.
Much work has been focused on the difficult problem of
identifying the structural characteristics of B cell epitopes
and a number of empirical approaches have been used in
attempts to predict such epitopes from the primary amino
acid sequence of proteins. The predictive value of these
methods for potential vaccine use is limited since they
identify linear B cell epitopes (Van Regenmortel, 2001). It
seems that B cell epitopes capable of inducing functional
antibody responses are, however, likely to be conformatio-
nal in nature and therefore, unlike linear epitopes cannot be
predicted from an analysis of the primary amino acid se-
quence (Mahler et al, 2003). Random phage display libraries
or solid phase combinatorial peptide libraries have been
used to identify peptides that mimic more complex epitopes
(Smith, 1991; Felici et al, 1995; Zwick et al, 1998; Aposto-
lopoulos et al, 1999; Yip et al, 2002). Peptide sequences
that bind to a wide range of ligands such as monoclonal
antibodies (mAb), receptors, and carbohydrate moieties have
been successfully identified (Apostolopoulos et al, 2002;
Monzavi-Karbassi et al, 2002; Cunto-Amesty et al, 2003).
In a previous study, we applied phage display technology
to define structural equivalents (mimotopes) of the epitope of
the mAb MAd18-5D7 on the cell adhesion molecule Mel-CAM
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(Hafner et al, 2002). We used a linear 28mer phage display
peptide library and identified two mimotopes, melcam mim1
and melcam mim2. By linear alignment using the BLAST
search algorithm it was possible to align the sequence of
melcam mim1 to the sequence of Mel-CAM between amino
acid positions 307 and 310 (LEPA). In this study, we com-
pared the ability of these mimotopes by themselves or
coupled to tetanus toxoid (TT) to induce Mel-CAM cross-
reactive antibodies. In addition, the potency of the B cell
epitopes in the induction of a peptide-specific Tcell reaction
was studied.
Results
Induction of anti-peptide-specific immune response To
investigate whether the mimotopes assume an immuno-
genic conformation corresponding to the natural epitope on
Mel-CAM, BALB/c mice (n¼5 per group) were immunized
with either the peptide mimics or the peptide mimics cou-
pled to TT. After a primary immunization and three boosts,
sera from individual mice were collected and tested for total
IgG anti-mimotope antibodies using ELISA technique. All
sera collected from mice immunized with uncoupled mi-
motopes contained antibodies that bound to the peptides in
dilution to at least 1:100. Sera from mice immunized with
TT-coupled mimotopes induced anti-mimotope-specific an-
tibodies with an endpoint-titer of at least 1:100,000. Pre-
immune sera, ch3 peptide, TT- or adjuvant-immunized mice
did not display any melcam mim1- or melcam mim2-spe-
cific antibody response (data not shown).
The subclass of IgG that is induced after immunization
serves as an indirect measure of the contribution of T helper
(Th)1-type cytokines versus Th2-type cytokines. In our ex-
periments, we measured production of IgG1 (Fig 1A,C) and
IgG2a (Fig 1B,D). In the sera of mice immunized with TT-
coupled mimotopes, IgG2a was the predominant isotype,
detectable in serum dilutions up to 1:40,640. Lower IgG1
antibody levels were measured in serum dilutions up to
1:10,160. Immunization with unconjugated mimotopes in-
duced only moderate peptide-specific IgG1 levels up to
1:40 (data not shown). Immunization experiments were re-
peated and resulted in similar antibody responses.
Mel-CAM-specific ELISA antibody assay and inhibition
assay Mel-CAM-specific antibody levels were detected by
ELISA. TT-coupled mimotopes induced significant Mel-
CAM-specific antibody responses (OD¼1.576  0.23 for
TT-melcam mim1-immunized mice, OD¼1.89  0.127 for
TT-melcam mim1-immunized mice) at a dilution of 1:500;
immunization with unconjugated mimotopes induced only
moderate Mel-CAM-specific IgG (OD¼0.759  0.9 for mel-
cam mim1-immunized mice, OD¼ 0.895  0.06 for melcam
mim2-immunized mice) at a dilution of 1:40. Control sera
from mice immunized with the ch3 peptide or TT did not
show any Mel-CAM-specific antibody response (data not
shown). We then investigated the specificity of the anti-mi-
motope antisera by inhibiting their binding to recombinant
Mel-CAM. As shown in Fig 2, pre-incubation of peptide im-
mune sera with melcam mim1 or melcam mim2 led to a
concentration-dependent binding inhibition of 47% for mel-
cam mim1 and 66% for melcam mim2; pre-incubation of
Figure1
Development of mimotope-specific antibodies. Microtiter plates
were coated with melcam mim1 and melcam mim2 and an ELISA assay
was performed to measure specific antibody levels. Sera of animals
(n¼5) immunized with tetanus toxoid (TT)-melcam mim1 and TT as
control were analyzed for (A) IgG1 and (B) IgG2a subclasses in dilutions
from 1:640 to 1:40,640 in triplicates. Sera of animals (n¼ 5) immunized
with TT-melcam mim2 were also analyzed for (C) IgG1 and (D) IgG2a
subclasses in dilutions from 1:640 to 1:40,640 in triplicates. &, pre-
immune sera; ’, immune sera.
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TT-conjugate immune sera with melcam mim1 or melcam
mim2 led to a concentration-dependent binding inhibition of
71% for melcam mim1 and 69% for melcam mim2. No in-
hibition was observed when immune sera were incubated
with the unrelated peptide mimic ch3.
Mel-CAM-specific immunoblot Recombinant Mel-CAM
was electrophoresed and blotted onto a nitrocellulose
membrane. Strips were incubated with serum pools or
mAb MAd18-5D7. Sera from mice immunized with melcam
mim1, melcam mim2, or TT conjugates reacted with the
recombinant Mel-CAM, whereas no reactivity was observed
when strips where incubated with pre-immune serum pool,
ch3 peptide, or TT-immunized mice (Fig 3).
Mimotope-specific cellular response We immunized
groups of mice with peptides and peptide conjugates. Sev-
en days after boosting mice were sacrificed and spleen
cells were collected. The data presented represent two in-
dependent experiments and were performed in triplicates.
As shown in Fig 4, spleen cells derived from melcam mim1-
or melcam mim2-immunized animals proliferated vigorous-
ly upon stimulation with melcam mim1 (stimulation index
(SI)¼5.068; c.p.m.: 20139  743) or melcam mim2 (SI¼
2.4; c.p.m.: 8375  389). In comparison with spleen cells
from naı¨ve mice stimulated with melcam mim1 or melcam
mim2, this proliferative response was significant (po0.05).
Spleen cells derived from mice immunized with TT-coupled
mimotopes were not activated by any of the mimotopes.
More interestingly, melcam mim1 activated spleen cells de-
rived from mice immunized with melcam mim2 (SI¼ 5.8;
c.p.m.: 20339  697), whereas no proliferation of spleen
cells was observed with the unrelated peptide mimic ch3 or
on naı¨ve spleen cells. The melcam mim1 and melcam mim2
cellular responses were antigen presenting cell (APC) de-
pendent, as detected by the addition of an anti-MHC class II
antibody that inhibit proliferation of the spleen cells (data
not shown).
Cytokine production in spleen cell cultures To charac-
terize the in vitro cytokine production of interleukin (IL)-2,
IL-4, IL-5, and interferon (IFN)-g levels were measured in
spleen cell cultures of mimotope-immunized or mimotope-
conjugate-immunized animals (n¼5 per group). Results are
summarized in Table I. Spleen cell cultures of mice immu-
nized with melcam mim1 or melcam mim2 released large
amounts of IFN-g and IL-2 in response to stimulation with
melcam mim1 or melcam mim2 (po0.01 compared with TT-
conjugate-immunized mice). Comparable levels of cytokine
production were observed in spleen cell cultures of melcam
mim2-immunized mice stimulated with melcam mim1, and
vice versa. Interestingly, TT-coupled mimotopes induced a
Th0-like cytokine profile. No cytokine release in response to
melcam mim1 or melcam mim2 was observed from spleen
cells of mice immunized with the unrelated peptide ch3, TT
or from spleen cells of naı¨ve mice. The data presented in
Table I represent the means  SD from two independent
experiments.
Figure 2
Melanoma cell-adhesion molecule (Mel-CAM)-specific ELISA inhi-
bition assay. ELISA was performed to evaluate antibodies specific to
recombinant Mel-CAM after immunization with (A) melcam mim1 and
melcam mim2 and (B) tetanus toxoid-coupled melcam mim1 and mel-
cam mim2. Sera were analyzed in a dilution 1:40 or 1:500, respectively.
Sera were pre-incubated with increasing concentrations of melcam
mim1, melcam mim2, or an unrelated peptide ch3 as the inhibitor, and
incubated with recombinant Mel-CAM coated to a microtiter plate.
Binding results are shown as inhibition (percentage) of binding of
mouse sera to Mel-CAM as a function of the free mimotope concen-
tration. ’, melcam mim1 serumpool/inhibition with melcam mim1; &,
melcam mim2 serumpool/inhibition with melcam mim2; 4 , melcam
mim1 serumpool/inhibition with ch3.
Figure3
Melanoma cell-adhesion molecule (Mel-CAM)-specific immuno-
blot. Eight micrograms of Mel-CAM were separated by 8% SDS-PAGE,
transferred to a nitrocellulose membrane and incubated with a pre-
immune serum pool (lane 1), a serum pool from melcam mim1-immu-
nized mice (lane 2), melcam mim2-immunized mice (lane 3), tetanus
toxoid (TT)-coupled melcam mim1-immunized mice (lane 4) and TT-
coupled melcam mim2-immunized mice (lane 5), monoclonal antibody
MAd18-5D7 (lane 6), and TT-immunized mice (lane 7). (B) Buffer control,
(C) isotype control; arrow indicates position of recombinant Mel-CAM.
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Tumor cell proliferation assay The biological effects of
the induced Abs were tested in vitro. MelJuso and MD3a
cells were incubated with mice sera or with mAb MAd18-
5D7. Incubation with TT-melcam mim1 sera enhanced 3H-
thymidine incorporation of 518A2 cells by 19.2%  2.1%,
with TT-melcam mim2 sera by 11.7%  0.98%, and with
mAb MAd18-5D7 by 11.6%  2.1% compared with un-
treated 518A2 cells (po0.01). The Mel-CAM-negative cell
line MD3a was not influenced by anti-TT-melcam mim1
or anti-TT-melcam mim2 antibodies. Anti-TT antibodies did
not affect the proliferation of any cell lines used (Fig 5).
Experiments were repeated three times under identical
conditions.
Complement-dependent cytotoxicity Sera from TT-mi-
motope-immunized mice were examined for their ability to
mediate complement-dependent lysis of Mel-CAM express-
ing target cells. Anti-TT-melcam mim1 and anti-TT-melcam
mim2 sera mediated low but specific lysis of MelJuso cells
up to 8.6%  0.9% (po0.01) compared with spontaneous
cell lysis (2.1%  0.7%). The data presented in Table II rep-
resent the mean values of three independent experiments.
Discussion
In this study, we demonstrated that immunization of mice
with two mimotopes that were derived from the melanoma-
associated cell adhesion molecule Mel-CAM were able to
induce anti-peptide antibodies that recognized the native
Mel-CAM antigen. In our previous work, we have shown
that both mimotopes were specific antigenic mimics of the
mAb MAd18-5D7 epitope of Mel-CAM (Hafner et al, 2002).
Nevertheless, antigenic mimicry does not guarantee im-
munogenic mimicry. Mimotope-based vaccine strategies
will only be effective if the induced mimotope-specific an-
tibody responses allow recognition of the targeted tumor
antigen. We demonstrated by ELISA as well as by im-
munoblot of recombinant Mel-CAM that the induced anti-
mimotope antibodies are Mel-CAM specific (Figs 2 and 3).
To provide further evidence that the induced IgG response
was directed toward the mAb MAd18-5D7 epitope on Mel-
CAM, we performed inhibition experiments. The synthetic
mimotopes blocked binding to Mel-CAM in a concentration-
dependant manner indicating that induced antibodies were
specific (Fig 2).
Synthetic mimotopes are attractive over other forms of
vaccination, because they are easily produced and free of
contaminating or toxic substances. In order to elicit efficient
humoral immune responses against mimotopes, the use of
carrier proteins seems to be necessary. Nevertheless, syn-
thetic mimotopes alone were able to induce antibodies with
sufficient affinities when they were applied at high density
(Olszewska et al, 2000). In particular, a carrier protein with T
helper activity will influence the immune response (Panina-
Bordignon et al, 1989). As a prototype of a carrier protein we
used TT and compared the effect of TT-coupled peptide
mimics or peptide mimics alone on the anti-Mel-CAM re-
sponse. We demonstrated that mice immunized with mel-
cam mim1 or melcam mim2 could elicit an IgG response
against Mel-CAM. Ig titers obtained by mimotope immuni-
zations were, however, substantially lower than those ob-
tained by immunization with TT as a carrier.
The role of cellular response of mimotopes and their in-
fluence in the formation of anti-mimotope antibodies
against tumor antigens has not been clarified so far in de-
tail. Therefore, we analyzed the humoral and cellular im-
mune responses to mimotopes previously generated by
biopannings of a 28mer-phage-displayed peptide library
with mAb MAd18-5D7. Upon stimulation with mimotope
peptides, we observed a significantly higher proliferation of
spleen cell cultures of mice that had been immunized with
uncoupled mimotopes (Fig 4). Both mimotopes induced the
production of Th1 cytokines in proliferating spleen cells in-
dicating that in addition to B cell epitopes they also con-
tained T cell epitopes (Table I). Interestingly, TT-coupled
mimotopes induced both Th1 and Th2 cytokines (Table I).
Nevertheless, IFN-g detected in supernatants collected
from spleen cell cultures that had been activated in vitro
by mimotopes supported Th1-type activation consistent
with the observed IgG2a production. Therefore, mimotope
immunization against Mel-CAM primes for both humoral
and cellular responses. This has been shown previously for
carbohydrate mimotopes (Monzavi-Karbassi et al, 2001,
2004). One might speculate that our mimotopes include
Figure 4
Cell proliferation assay on splenocytes of mice immunized with the
indicated mimotope or tetanus-coupled mimotope. Splenocytes
were co-cultured with (A) melcam mim1or (B) melcam mim2. SI, stim-
ulation index¼ ratio of mean proliferation with peptide and medium
control values.
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cytotoxic T cell epitopes. This might be an explanation for
high cellular proliferation and high IFN-g release of uncou-
pled mimotopes.
It is now accepted that a Th1-dominant immunity, which
is regulated by IL-12 and IFN-g, plays a pivotal role in the
eradication of tumors in vivo (Portielje et al, 2003). A Th1
response with the expression of the IgG2a isotype is a de-
sirable response as IgG2a Abs are opsonizing and com-
plement-fixing (Hart et al, 2004). The Th1-biased immune
response of both mimotopes was further indicated by an
increase in the IgG2a/IgG1 ratio in the TT-coupled mimo-
tope-immunized mice. However, immunization with TT-cou-
pled mimotopes induced IL-4 as well as IFN-g producing
cells (Table I). These results indicate that both the overall
magnitude of the humoral and cellular immune responses
were significantly affected by the carrier protein. The fact
that immunization with uncoupled mimotopes induced high
IFN-g levels but a low antibody response indicates that the
potential of mimotopes to induce a certain quality of im-
mune response can be modulated by a selected carrier
system. Mimotope vaccination without carrier proteins may
favorably induce a cellular/cytotoxic anti-tumor response.
This concept will need further clarification.
Anti-Mel-CAM antibodies can affect tumor growth by
both direct and indirect mechanisms (Mills et al, 2002;
Table I. Release of cytokines from splenocytes of mice immunized with melcam mim1 or melcam mim2 and their
corresponding TT conjugatesa
Cytokine release Immunization with
Stimulation in vitro with
melcam mim1 melcam mim2 ch3
IFN-g melcam mim1 513.27  30.22 159.64  10.98 5.74  0.46
melcam mim2 151.33  13.78 227.92  20.79 2.30  0.10
TT melcam mim1 53.48  5.42 27.55  3.52 0.00
TT melcam mim2 51.86  4.12 98.55  10.97 0.00
IL-2 melcam mim1 471.07  57.34 66.73  4.54 0.00
melcam mim2 0.00 112.91  15.4 0.00
TT melcam mim1 0.00 0.00 0.21  0.19
TT melcam mim1 0.00 0.07  0.01 0.20  0.43
IL-4 melcam mim1 10.16  1.52 0.00 0.21  0.01
melcam mim2 0.00 10.02  2.07 0.30  0.01
TT melcam mim1 31.49  2.54 13.28  1.38 4.04  0.21
TT melcam mim1 2.99  0.39 17.66  1.67 3.42  0.42
IL-5 melcam mim1 13.85  1.84 0.37  0.01 0.00
melcam mim2 0.54  0.04 42.03  0.24 0.00
TT melcam mim1 0.90  0.02 2.26  0.62 0.00
TT melcam mim1 0.00 0.90  0.05 0.00
aResults are presented as mean  SD after subtraction of baseline. Cytokine release is shown in picograms per milliliter.
IFN, interferon; IL, interleukin; TT, tetanus toxoid
Figure 5
Melanoma cell proliferation assay. 3H-thymidine proliferation assay
demonstrating the effects of the murine IgG on MelJuso and MD3a cell
line growth.
Table II. Complement-dependent cell lysisa
Incubation with immune sera against
% lysis of target cell
MelJuso MD3a
TT melcam mim1 8.6  0.9 0.0
TT melcam mim2 5.2  0.7 0.5  0.03
TT 1.2  0.1 0.9  0.2
aTarget cells were incubated with mouse sera and rabbit serum as a
source of complement.
Inactivated rabbit serum was used to distinguish specific from spon-
taneous cell lysis.
Percentage of lysis were calculated using the formula: % lysis¼
[(experimentaltarget spontaneous)/(target maximumtarget spontane-
ous)]  100.
TT, tetanus toxoid.
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McGary et al, 2003). The direct effect involves homotypic
interactions between melanoma cells and heterotypic inter-
actions between melanoma cells and endothelial cells (Shih,
1999). Anti-TT-melcam mim1 antibodies and anti-TT-
melcam mim2 antibodies led to a 19.2%  2.1% or
11.7%  0.98% enhanced proliferation of MelJuso me-
lanoma cells, respectively. This is comparable with the pro-
liferative effect of mAb MAd18-5D7 on Mel-CAM-positive
tumor cells in vitro (Fig 5). The indirect mechanisms also
involve complement-dependent cytotoxicity. We were able
to demonstrate that anti-TT-melcam mim1 as well as anti-
TT-melcam mim2 antibodies in association with rabbit com-
plement led to low but specific cell lysis of MelJuso cells
(Table II).
The results of this study provide evidence that synthetic
mimotopes can resemble T and B cell epitopes of Mel-CAM
both as an immunogen and mimic of the natural antigen and
suggest that phage display peptide libraries have a broad
application for the design of anti-cancer vaccines. A new
generation of anti-cancer vaccines could possibly consist of
a mixture of mimotopes selected by using tumor-specific
mAb.
Materials and Methods
Peptide mimics, recombinant Mel-CAM, cell lines, and anti-
bodies The peptides, GRALPGTAEWTSYPGWTSRLKNLEPAVG
(melcam mim1) and RVKHMLVGASSRVPGFFSSLPGFQGPFT
(melcam mim2), and an unrelated peptide (ch3) were synthesized
by piCHEM (Graz, Austria). The purity of the peptides was greater
than 95% as assessed by HPLC. The selection process of melcam
mim1 and melcam mim2 was described elsewhere (Hafner et al,
2002). The recombinant extracellular Mel-CAM domain was a gift
of M. Herlyn (The Wistar Institute, Philadelphia, Pennsylvania) and
described elsewhere (Shih et al, 1997). The human melanoma cell
line MelJuSo (Lehmann et al, 1987) that expresses high levels of
Mel-CAM and the melanoma cell line MD3a (Versteeg et al, 1989)
with no detectable expression of Mel-CAM were cultured in RPMI-
1640 medium supplemented with 10% fetal calf serum and anti-
biotics (Gibco, Invitrogen, Carlsbad, California). MAd18-5D7 is a
mouse IgM mAb and was selected on the basis of its activity of
enhancing Mel-CAM-mediated adhesion in aggregation assays (J.
P. Johnson, Institute of Immunology, University of Munich, Munich,
Germany, unpublished results).
Coupling of mimotopes Mimotopes were coupled to the carrier
protein TT (Berna, Bern, Switzerland) using the heterobifunctional
cross-linking reagent m-maleimidobenzoyl-N-hydroxysuccinimide
(MBS) (Pierce Endogen, Rockford, Illinois). The amino groups of
the carrier protein were first activated by the addition of a 25-fold
molar excess of MBS for 30 min at room temperature. Excess MBS
was removed by a desalting column (PD-10 column, Amersham
Bioscience, Little Chalfont, UK). In a second step, peptides were
added in a molar ratio of 40:1 peptide-to-carrier protein. Cross-
linking occurred to the cysteine residues on the peptides within 3 h
at room temperature. Unbound peptides were removed by dialysis
against phosphate-buffered saline (PBS).
Immunization with synthetic peptide mimics or with TT-cou-
pled peptide mimics Groups of five 6-wk-old female BALB/c
mice (Charles River, Sulzfeld, Germany) were immunized intraperi-
toneally with synthetic mimotopes or mimotopes coupled to TT.
Each injection delivered 20 mg peptide in 100 mL 0.9% sodium
chloride containing 50 mL Al(OH)3 as adjuvants. The control group
received TT and adjuvants alone. The immunizations were per-
formed four times in 21-d intervals. Seven days after the last
immunization the animals were sacrificed. Mice were bled prior to
immunization, before each immunization and 1 wk after the last
immunization. Experiments were performed twice under identical
experimental conditions. The Animal Experimentation Committee
of the University of Vienna and the Ministry of Education, Science
and Culture, Vienna, Austria approved the experiments. The study
was conducted according to Declaration of Helsinki Principles.
Peptide-specific ELISA antibody assays Microtiter wells (Max-
isorb, Nunc, Roskilde, Denmark) were coated overnight at 41C with
melcam mim1 or melcam mim2 (3 mg per mL coating buffer 50 mM
NaHCO3, pH 9.4), blocked with 5% milk powder in PBS for 2 h and
washed with PBS/0.05% Tween-20. Sera were serially diluted into
ELISA wells containing blocking buffer. Isotype specific or total IgG
goat anti-mouse secondary antibodies conjugated to alkaline
phosphatase (Sigma, St Louis, Missouri) were used for detection
of bound antibodies. ELISA were developed by addition of p-nit-
rophenylphosphate (Sigma). The absorbance was measured at
405 nm. Endpoint titers were defined as the dilution producing an
OD equal to twice the ELISA background.
Mel-CAM-specific ELISA antibody assay and inhibition as-
say ELISA for reactivity to recombinant Mel-CAM was performed
by coating wells with 2 mg per mL coating buffer of recombinant
Mel-CAM. Sera were serially diluted in blocking buffer and added
to the blocked microtiter plates. For inhibition experiments sera
were diluted 1:40 (for uncoupled mimotopes) or 1:500 (for TT-cou-
pled mimotopes), and incubated overnight at 41C with increasing
amounts of melcam mim1, melcam mim2, or ch3 (0 mg per mL up
to 1 mg per mL). Subsequently, total IgG goat anti-mouse sec-
ondary antibody conjugated to alkaline phosphatase (Sigma) was
used for detection of bound antibodies. ELISA was developed by
addition of p-nitrophenylphosphate (Sigma). The absorbance was
measured at 405 nm.
Immunoblot Five micrograms of recombinant Mel-CAM were
electrophoresed on an 8% polyacrylamide gel and transferred on-
to a nitrocellulose membrane (Schleicher and Schuell, Keene, New
Hampshire). Sera were diluted 1:100 (for TT-coupled mimotopes)
or 1:40 (for uncoupled mimotopes) in 5% MTBS/0.5% Tween-20
and added to the blocked nitrocellulose membrane. mAb MAd18-
5D7 was used as a positive control and is described elsewhere
(Hafner et al, 2002). Bound antibodies were visualized using an AP-
conjugated anti-mouse IgG (g-specific) (Sigma) or an AP-conju-
gated anti-mouse IgM (m-specific) (Sigma), respectively, followed
by equilibration in AP-buffer (0.1 M Tris base, pH 9.5, 0.1 M NaCl, 1
mM MgCl2) and development with nitroblue tetrazolium and 5-
bromo-4-chloro-3-indolyl phosphate-p-toluidine.
Lymphocyte cell proliferation and cytokine production in
spleen cell cultures Spleen cells from mimotope-sensitized and
control animals were used for detection of T cell proliferation.
Briefly, 2  106 cells were incubated without or with mimotopes (2
mg per well), TT (0.2 mg per well), or concanavalin A (0.2 mg per well)
(Sigma). After 3 d of incubation, 1 mCi of 3H-thymidine was added
to each well and incubation continued for 16 h. The plates were
harvested and the amount of incorporated 3H-thymidine was
counted on a 1205 Betaplate Liquid Scintillation Counter (Wallac
Oy, Turku, Finland). Stimulation indices were calculated using the
formula: SI¼ ratio of mean proliferation with peptide and medium
control values. For determination of IL-2, IL-4, IL-5, and IFN-g
production, spleen cells were cultured with mimotopes, TT, or
concanavalin A in 48-well plates (Costar, Cambridge, Massachu-
setts) at a concentration of 5  106 per well. Supernatants were
collected from the cultures 48 h after in vitro activation and the
concentrations of IL-2, IL-4, and IL-5 were measured by purchased
appropriate ELISA kits according to the guideline of the manufac-
turer (Pierce Endogen). IFN-g levels were measured in 96-well
plates (Nunc) and coated with rat anti-mouse IFN-g (Pierce Endo-
gen) at a concentration of 0.5 mg per mL carbonate buffer, pH
9.6 for 6 h at room temperature. Thereafter, biotin-labeled rat
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anti-mouse IFN-g antibodies (Pierce Endogen) were applied fol-
lowed by peroxidase-conjugated streptavidin. For color develop-
ment tetramethylbenzidin substrate was used and the absorbance
measured at 450 nm. The sensitivity of this assay was 15 pg per
mL. Results reflect the measured cytokine levels in picograms per
milliliter after subtraction of baseline levels of non-stimulated cell
cultures.
Tumor cell proliferation assay Tumor cells were plated in 96-well
micotiter plates (Costar, Corning, New York) at a density of 5  104
cells per well for MelJuso and MD3a cell lines. Cells were allowed
to adhere overnight at 371C. Mouse sera of TT-melcam mim1 or TT-
melcam mim2 vaccinated animals or mAb MAd18-5D7 were add-
ed to the cells diluted up to 1:100 and incubated for 72 h at 371C.
Cells were pulsed with 0.5 mCi 3H-thymidine per well for 6 h and
harvested. The incorporated 3H-thymidine was measured in a b-
counter (Wallac Oy). Percentage of inhibition was calculated by
comparing the counts per minute values of treated cells with those
of untreated cells.
Complement-dependent cytotoxicity assay Promega CytoTox
96 Non-Radioactive Cytotoxicity Assay (Promega Corp., Madison,
Wisconsin) was used for measurement of cell lysis. A naı¨ve rabbit
serum in a final dilution 1:5 was used as a source of complement.
To calculate unspecific cell lysis, inactivated (561C/30 min) serum
was used. MelJuso and MD3a cells were used as target cells.
1  104 cells per well were plated and inactivated mice sera, di-
luted 1:100, were added. Plates were incubated for 1 h at 371C.
Thereafter complement was added and incubated for 2 h. Assays
were performed according to the manufacturer’s instructions. Per-
centages of lysis were calculated using the formula: % lysis¼
[(experimentaltarget spontaneous)/(target maximumtarget
spontaneous)]  100.
Statistical analysis The data of tumor cell proliferation and
complement-dependent cytotoxicity (CDC) experiments were eval-
uated statistically by the Pearson w2 significance test and the
Mann–Whitney U test was used to statistically evaluate lymphocyte
cell proliferation and cytokine production in spleen cell cultures.
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